The therapeutical approach for patients with mCRC requires the definition of the therapeutic strategy that must consider the tumor and the patients features. Based on the ESMO and AIOM guidelines, specific situations have been investigated in order to share useful elements for clinical practice: the RAS patient mutated, the patient RAS wild-type and the elderly patient. Moreover, the meeting has been an opportunity for a look at the future of the target therapies and of the immunotherapy. All these key issues have been discussed with the contribution of Italian and internationally renowned speakers.